共 50 条
- [32] Low-dose ramipril (1.25 mg/day) does not decrease cardiovascular events in type 2 diabetes patients with microalbuminuria/proteinuria:: the DIABHYCAR (type 2 DIABetes, HYpertension, CArdiovascular events and Ramipril) studyDIABETOLOGIA, 2002, 45 : A64 - A64Marre, MLièvre, MChatellier, GVasmant, DMann, JPassa, PMenard, J
- [33] Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Feng, MeiTang, Li yuFan, MingLi, LuWang, ShuoYin, Pin qingAi, Yu hangZhao, ShanYin, YuLiu, Qun dengRen, Zhou yaLi, JieLi, FangLang, Jinyi
- [34] Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trialDiabetology International, 2017, 8 (4) : 383 - 391Kameda A.Nakamura A.Kondo Y.Kimura M.Terauchi Y.
- [35] The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than 1 year of treatment: results from an ongoing phase 2b clinical trial (ARC002), including low-dose (300 mg/day) and high-dose (2000 mg/day) maintenance regimensALLERGY, 2016, 71 : 105 - 105Rachid, R. A.Bird, J. A.Spergel, J. M.Jones, S. M.Assa'ad, A. H.Vickery, B.Wang, J.Leonard, S. A.Laubach, S. S.Kim, E. H.Davis, B. P.Welch, M. J.Heimall, J.Cianferoni, A.MacGinnitie, A. J.Crestani, E.Bennett, S.Elfont, R. M.Burks, A. W.
- [36] Ixekizumab treatment shows a neutral impact on the glucose and lipid profile of patients with moderate-to-severe psoriasis: Results from UNCOVER-1,-2, and-3JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260Wu, J. J.Egeberg, A.Solomon, J. A.Osuntokun, O.Goldblum, O.Moriarty, S.Zhao, F.Korman, N.Vincent, M.
- [38] Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 StudiesJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 24 - 25Armstrong, April W.Strober, BruceGordon, KennethZhuo, JoeBecker, BrandonKisa, RenataThroup, JohnKim, JonghyeonDirschka, ThomasPapp, Kim Alexander
- [39] A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)FRONTIERS IN ONCOLOGY, 2024, 14Demidov, LevKharkevich, GalinaPetenko, NataliaMoiseenko, VladimirProtsenko, SvetlanaSemiglazova, TatianaZimina, AnastasiaKovalenko, NadezhdaFadeeva, NataliaKirtbaya, DmitryBelogortsev, IgorTantsyrev, DenisOdintsova, SvetlanaNesterova, AlfiaVorontsova, KarinaMakarycheva, YuliaLinkova, YuliaZinkina-Orikhan, ArinaSiliutina, AnnaSorokina, IrinaLiaptseva, DariaChistyakov, VladimirLutsky, Anton
- [40] A 3-YEAR-OLD GIRL HAS STEROID-RESPONSIVE NEPHROTIC SYNDROME, BUT PROTEINURIA RECURS PERSISTENTLY WHEN THE DOSE OF PREDNISOLONE IS REDUCED TO 1.5 MG KG PER DAY OR WHEN SHE IS PLACED ON HIGH-DOSE ALTERNATE-DAY STEROIDS - THE PROTEINURIA IS ONLY MODERATE (ALBUSTI 1+-2+) AND THERE IS NO EDEMA - HOW SHOULD THIS CHILD BE MANAGEDPEDIATRIC NEPHROLOGY, 1992, 6 (06) : 522 - 522NIAUDET, P